By Gwendolyn Wu
Published September 28, 2026
In the rapidly evolving landscape of autoimmune disease research, a significant paradigm shift is underway. For years, the gold standard for severe immunological conditions has been the lifelong, often debilitating administration of chronic immunosuppressants and steroids. However, the success of CAR-T cell therapies—originally engineered to hunt down cancer cells—has opened a new frontier: the possibility of a "one-and-done" immune system reset.
Adicet Bio has emerged as a key player in this transition, recently releasing early-stage trial data that suggests its "gamma delta" cell therapy, known as prula-cel, could outperform traditional, personalized CAR-T approaches in treating lupus. By moving away from the autologous models that have recently faced safety setbacks, Adicet is positioning its allogeneic, donor-derived platform as a safer, more scalable alternative for patients suffering from systemic lupus erythematosus (SLE).
The Main Facts: A New Approach to Immune Reset
The central promise of CAR-T (chimeric antigen receptor T-cell) therapy in autoimmune diseases is the selective elimination of autoreactive B cells—the cells responsible for the erratic immune response in conditions like lupus. While initial studies using conventional "alpha beta" T cells have demonstrated remarkable efficacy in putting lupus into remission, the manufacturing and safety hurdles have been substantial.
Adicet’s prula-cel utilizes gamma delta T cells, a unique subset of the immune system known for its ability to recognize stress signals and tumors without triggering the same intensity of inflammatory response as their alpha beta counterparts. Because prula-cel is "allogeneic"—sourced from healthy donors rather than the patient themselves—it offers a "ready-to-use" product that bypasses the weeks-long, highly expensive manufacturing process required for personalized (autologous) therapies.
According to data released on September 28, 2026, the efficacy profile of prula-cel appears competitive with, if not superior to, established benchmarks for CAR-T treatments in autoimmune settings. By targeting the root cause of the immune dysfunction rather than just masking symptoms, Adicet aims to move beyond the status quo of chronic, daily medication.
Chronology: The Evolution of Cell Therapy in Autoimmunity
The journey toward using cell therapy for autoimmunity did not happen overnight. The timeline of this medical evolution reflects both the immense promise and the inherent risks of bioengineering:
- 2022: Adicet Bio first signaled the potential of its gamma delta platform, reporting promising results in oncology trials targeting lymphoma. This established the safety and biological viability of its platform, though the company’s stock valuation would eventually face headwinds in the years that followed.
- 2024: High-profile studies published in journals like The New England Journal of Medicine proved that CAR-T could effectively "reset" the immune systems of lupus patients, triggering a wave of investment and interest from pharmaceutical giants.
- Mid-2026: The industry faced a sobering reality check. Major pharmaceutical players, including Novartis and Bristol Myers Squibb, were forced to halt or pause trials of their personalized CAR-T therapies. The reason? A series of alarming safety signals, including rare but fatal immune complications, cast doubt on the safety profile of the current generation of autologous CAR-T treatments for non-cancer indications.
- September 2026: Adicet releases the data for prula-cel, providing a potential "path out" for the industry. By demonstrating that the gamma delta approach carries a lower risk of cytokine-related complications, the company re-ignited investor interest in the viability of cell therapy for systemic autoimmune diseases.
Supporting Data: Safety and Efficacy in Focus
The primary concern regarding CAR-T therapy has always been the "cytokine storm"—an aggressive inflammatory response that can lead to organ failure or death.
Adicet CEO Chen Schor noted in an email to BioPharma Dive that the biological architecture of gamma delta cells is inherently safer. "Gamma delta cells secrete fewer and lower levels of the inflammatory cytokines that typically spark the severe immune-related side effects seen in alpha beta treatments," Schor explained.
Clinical Metrics:
- Cytokine Release Syndrome (CRS): In early testing, approximately 25% of patients treated with prula-cel experienced mild-to-moderate CRS. While this remains a factor, it is significantly lower than the incidence and severity rates observed in trials for other CAR-T candidates.
- Infection Rates: More than half of the study participants reported infections, with roughly 8% classified as Grade 3 or higher. While this is a metric requiring close observation, experts suggest that compared to the systemic vulnerability caused by long-term, high-dose steroids, the transient risk of infection represents a favorable risk-benefit trade-off.
- Comparative Efficacy: Jefferies analyst Dennis Ding highlighted that while the study remains small, the early data is "impressive." While peer cell therapy manufacturers have reported complete response rates in the neighborhood of 40%, Adicet’s early metrics are already matching or trending toward those same benchmarks, suggesting that the "off-the-shelf" nature of the product does not come at the expense of clinical power.
Official Responses and Industry Outlook
The industry’s reaction to the news has been a mix of cautious optimism and market volatility. Following the announcement, shares in Adicet dropped by 22% by mid-morning. Market analysts attribute this not to the clinical data itself, but to the broader sector fatigue that has plagued biotech stocks, particularly those that peaked during the 2022 cell therapy boom.
However, the consensus among observers like Dennis Ding remains bullish on the underlying science. "The data could encourage pharmaceutical companies to start migrating toward more elegant solutions like gamma delta T cells," Ding noted.
For the company, the mission is clear: to pivot away from a market that is currently wary of the "personalized" model. Adicet is now in discussions with regulators to explore an expanded pivotal study. The focus is expected to broaden beyond patients with lupus nephritis to include a wider spectrum of lupus sufferers, potentially changing the standard of care for millions.
Implications: A New Era for Autoimmune Patients
The implications of Adicet’s progress extend far beyond a single drug. If prula-cel continues to show success, it could provide the validation needed for a wider transition toward allogeneic "off-the-shelf" cell therapies.
The Patient Perspective
For the average lupus patient, the "standard of care" currently involves a lifetime of balancing the side effects of immunosuppressants—such as bone density loss, infection risk, and metabolic changes—against the disease itself. A one-time intervention that resets the immune system represents a monumental shift in quality of life.
The Regulatory Path
Regulators have been understandably cautious given the recent deaths reported in other CAR-T trials. Adicet’s challenge will be to demonstrate that its platform is not only efficacious but consistently safe across diverse patient demographics. If the company can prove that the gamma delta cell’s unique biology prevents the "over-reaction" of the immune system, they may secure a faster, more favorable path to FDA approval than their competitors.
Future Applications
Beyond lupus, the "immune reset" concept is being studied for a variety of inflammatory conditions, including systemic sclerosis and potentially even some forms of multiple sclerosis. If the gamma delta model proves successful, it could become the foundation for a new class of "immunotherapy for everything," shifting the biotech industry away from managing chronic illness and toward potentially curative interventions.
As the industry digests the September data, the message from the scientific community is becoming increasingly clear: the next generation of autoimmune treatment will be defined not just by what it kills, but by how precisely it can reboot the body’s own defenses. Adicet Bio, with its gamma delta strategy, has placed itself at the front of that line, offering a glimpse into a future where "chronic" is no longer the final word in a patient’s diagnosis.
